Functional characterization of 32 CYP2C9 allelic variants
作者： Y Niinuma , T Saito , M Takahashi , C Tsukada , Mi Ito
DOI: 10.1038/TPJ.2013.22
关键词:
摘要: Genetic variations in cytochrome P450 2C9 (CYP2C9) contribute to interindividual variability the metabolism of clinically used drugs such as warfarin and tolbutamide. We functionally characterized 32 types allelic variant CYP2C9 proteins. Recombinant proteins generated using a heterologous expression system are useful for comparing functional changes expressed from low-frequency alleles. Wild-type its 31 variants were found be transiently COS-7 cells, enzymatic activity was S-warfarin representative substrate. Among tested, CYP2C9.18, CYP2C9.21, CYP2C9.24, CYP2C9.26, CYP2C9.33 CYP2C9.35 exhibited no enzyme activity, 12 showed significantly decreased activity. In vitro analysis should predicting phenotypes application personalized drug therapy.
nature.com
sci-hub.se 参考文章(33)
O Gotoh, Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. Journal of Biological Chemistry. ,vol. 267, pp. 83- 90 ,(1992) , 10.1016/S0021-9258(18)48462-1
M E Veronese, C J Doecke, P I Mackenzie, M E McManus, J O Miners, D L Rees, R Gasser, U A Meyer, D J Birkett, Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochemical Journal. ,vol. 289, pp. 533- 538 ,(1993) , 10.1042/BJ2890533
M. B. Faletto, J. A. Goldstein, L. S. Kaminsky, S. M. F. De Morais, D. A. Dunbar, Correlation of human cytochrome P4502C substrate specificities with primary structure : warfarin as a probe Molecular Pharmacology. ,vol. 43, pp. 234- 239 ,(1993)
Bo Wang, Jing Wang, Shui-Qing Huang, Hai-Hao Su, Shu-Feng Zhou, Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance Current Drug Metabolism. ,vol. 10, pp. 781- 834 ,(2009) , 10.2174/138920009789895480
T Hanatani, T Fukuda, M Ikeda, S Imaoka, T Hiroi, Y Funae, J Azuma, CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenomics Journal. ,vol. 1, pp. 288- 292 ,(2001) , 10.1038/SJ.TPJ.6500063
Pamela A. Williams, Jose Cosme, Alison Ward, Hayley C. Angove, Dijana Matak Vinković, Harren Jhoti, Crystal Structure of Human Cytochrome P450 2C9 with Bound Warfarin Nature. ,vol. 424, pp. 464- 468 ,(2003) , 10.1038/NATURE01862
Allan E. Rettie, Larry C. Wienkers, Frank J. Gonzalez, William F. Trager, Kenneth R. Korzekwa, Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. ,vol. 4, pp. 39- 42 ,(1994) , 10.1097/00008571-199402000-00005
A. E. Rettie, The pharmocogenomics of warfarin: closing in on personalized medicine. Molecular Interventions. ,vol. 6, pp. 223- 227 ,(2006) , 10.1124/MI.6.4.8
Yuet Kin Leung, John W Ho, Inhibitory effect of nicotine and its metabolites on tolbutamide hydroxylation in rat liver microsomes Journal of Biochemical and Biophysical Methods. ,vol. 36, pp. 87- 94 ,(1998) , 10.1016/S0165-022X(98)00003-7
Keiko Maekawa, Hiromi Fukushima-Uesaka, Masahiro Tohkin, Ryuichi Hasegawa, Hiroshi Kajio, Nobuaki Kuzuya, Kazuki Yasuda, Manabu Kawamoto, Naoyuki Kamatani, Kazuko Suzuki, Tatsuo Yanagawa, Yoshiro Saito, Jun-ichi Sawada, Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese Pharmacogenetics and Genomics. ,vol. 16, pp. 497- 514 ,(2006) , 10.1097/01.FPC.0000215069.14095.C6